We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter International: Health Canada Okays AMIA APD System
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) is forging ahead with its expansion plans in Canada with the launch of AMIA Automated Peritoneal Dialysis (APD) System (late 2016) on the SHARESOURCE Connectivity Platform, which recently received approval from Health Canada.
Last October, the AMIA APD system with SHARESOURCE Connectivity was also sanctioned by the FDA. The system offers peritoneal dialysis for patients suffering from end-stage renal disease (ESRD). Peritoneal dialysis is a medical procedure to remove waste products from a patient’s blood when the kidneys are not entirely functional.
Notably, the AMIA APD system is the only FDA-approved product in the U.S. and Canada that possesses patient-friendly features such as voice guidance, a touchscreen control panel and the SHARESOURCE two-way connectivity platform.
With the help of the SHARESOURCE platform, physicians will be able to efficiently access treatment data of home patients and provide individual prescriptions remotely. Moreover, the AMIA APD system comes with sophisticated, animated graphics and automatic step-by-step commands, which will increase the effectiveness of home therapy guidance and management for ESRD patients.
According to a report by market research firm MarketsandMarkets, the global peritoneal dialysis market is expected to reach a worth of approximately $83.21 billion by 2018. Approximately one in 10 Canadians have chronic kidney disease and about 24,000 of those individuals have ESRD and are on dialysis therapy.
We believe that the favorable market trend presents significant growth opportunities for Baxter. We also note that the company is focused on expanding its ESRD product portfolio and has recently showcased THERANOVA, a new class of medium cut-off (MCO) dialysers. THERANOVA is capable of filtering mid and large-sized toxins that standard haemodialysis fails to remove from end-stage kidney disease patients.
Baxter has already received CE marking for THERANOVA in Europe, Australia and New Zealand, among other countries. The company announced that the dialyser will be available in select countries in 2016, with additional launches planned for 2017. The launch will definitely expand Baxter’s in-center haemodialysis portfolio, particularly in international markets.
Baxter expects the renal product category to exceed $17 billion by 2021, on 6% growth in patient population. Aging population, expanding access in emerging markets and growing adoption of home therapies are the key catalysts. We believe the launch of AMIA APD system with the SHARESOURCE Connectivity in Canada and the upcoming launch of THERANOVA will help it to achieve this target.
Zacks Rank & Key Picks
Baxter carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical space are ICU Medical (ICUI - Free Report) , Boston Scientific (BSX - Free Report) and NuVasive . All the three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Baxter International: Health Canada Okays AMIA APD System
Baxter International Inc. (BAX - Free Report) is forging ahead with its expansion plans in Canada with the launch of AMIA Automated Peritoneal Dialysis (APD) System (late 2016) on the SHARESOURCE Connectivity Platform, which recently received approval from Health Canada.
Last October, the AMIA APD system with SHARESOURCE Connectivity was also sanctioned by the FDA. The system offers peritoneal dialysis for patients suffering from end-stage renal disease (ESRD). Peritoneal dialysis is a medical procedure to remove waste products from a patient’s blood when the kidneys are not entirely functional.
Notably, the AMIA APD system is the only FDA-approved product in the U.S. and Canada that possesses patient-friendly features such as voice guidance, a touchscreen control panel and the SHARESOURCE two-way connectivity platform.
With the help of the SHARESOURCE platform, physicians will be able to efficiently access treatment data of home patients and provide individual prescriptions remotely. Moreover, the AMIA APD system comes with sophisticated, animated graphics and automatic step-by-step commands, which will increase the effectiveness of home therapy guidance and management for ESRD patients.
BAXTER INTL Price and Consensus
BAXTER INTL Price and Consensus | BAXTER INTL Quote
According to a report by market research firm MarketsandMarkets, the global peritoneal dialysis market is expected to reach a worth of approximately $83.21 billion by 2018. Approximately one in 10 Canadians have chronic kidney disease and about 24,000 of those individuals have ESRD and are on dialysis therapy.
We believe that the favorable market trend presents significant growth opportunities for Baxter. We also note that the company is focused on expanding its ESRD product portfolio and has recently showcased THERANOVA, a new class of medium cut-off (MCO) dialysers. THERANOVA is capable of filtering mid and large-sized toxins that standard haemodialysis fails to remove from end-stage kidney disease patients.
Baxter has already received CE marking for THERANOVA in Europe, Australia and New Zealand, among other countries. The company announced that the dialyser will be available in select countries in 2016, with additional launches planned for 2017. The launch will definitely expand Baxter’s in-center haemodialysis portfolio, particularly in international markets.
Baxter expects the renal product category to exceed $17 billion by 2021, on 6% growth in patient population. Aging population, expanding access in emerging markets and growing adoption of home therapies are the key catalysts. We believe the launch of AMIA APD system with the SHARESOURCE Connectivity in Canada and the upcoming launch of THERANOVA will help it to achieve this target.
Zacks Rank & Key Picks
Baxter carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical space are ICU Medical (ICUI - Free Report) , Boston Scientific (BSX - Free Report) and NuVasive . All the three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>